BioLife Sciences Inc. (BLFE)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Breakdown | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | -884.3 Thousand | 17.00 | -12.51 Thousand | -18.63 Thousand |
| Net Income | - | - | -1.26 Million | -1134.00 | -52.71 Thousand | -340.38 Thousand |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | - | 379.11 Thousand | 1151.00 | 25.24 Thousand | 21.75 Thousand |
| Other non-cash items | - | - | -410.66 Thousand | -1151.00 | -10.29 Thousand | 300 Thousand |
| Investing Cash Flow | - | - | -961.00 | - | - | - |
| Investments in PPE | - | - | -961.00 | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | - | - | 875.79 Thousand | - | 1500.00 | 30.96 Thousand |
| Debt repayment | - | - | -875.79 Thousand | - | -1500.00 | -30.96 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | - | - | - | - | - |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | 414.96 Thousand | 1151.00 | 25.24 Thousand | - |
| Inventory | - | - | 18.00 | - | - | - |
| Other working capital | - | - | -35.87 Thousand | - | - | 21.75 Thousand |
| Cash at beginning of period | - | 34.74 Thousand | 17.00 | 1320.00 | 12.33 Thousand | - |
| Cash at end of period | - | 34.74 Thousand | 34.74 Thousand | 17.00 | 1320.00 | 12.33 Thousand |
| Capital Expenditure | - | - | -961.00 | - | - | - |
| Effect of forex changes on cash | - | - | 44.19 Thousand | - | - | - |
| Net cash flow / Change in cash | - | - | 34.72 Thousand | -1303.00 | -11.01 Thousand | 12.33 Thousand |
| Free Cash Flow | - | - | -885.26 Thousand | 17.00 | -12.51 Thousand | -18.63 Thousand |
| Breakdown | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY | 2022 Q4 | 2022 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | - | - | - | - | - |
| Other non-cash items | - | - | - | - | - | - |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | - | - | - | - | - | - |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | - | - | - | - | - |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | - | - | - | - | - |
| Cash at beginning of period | - | - | - | - | - | - |
| Cash at end of period | - | - | - | - | - | - |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
YAYLA
GDXRF
VINS
NAFS
600732
BKGFF